As quoted in the press release:
Aequus Pharmaceuticals (“Aequus” or the “Company“), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, and Ehave, a healthcare bioinformatics company whose platform efficiently captures, integrates, and delivers high-quality clinical data and treatment tools, have entered into a collaboration agreement whereby Aequus will incorporate Ehave’s bioinformatics platform to enhance and streamline data management processes for Aequus-sponsored clinical trials studying specific Cannabinoid-rich formulations for treating a number of neurological disorders. The Companies had been working together under a previously announced Letter of Intent established in August 2017.
The terms of the agreement are similar to that of the original Letter of Intent. Aequus will pay Ehave a per-patient fee for trials conducted using Ehave’s platform and Aequus will receive patient assessment, diagnostic and therapeutic outcomes and side-effect profile content from formal and informal studies conducted using the Ehave platform, subject to standard patient consent and clinical research ethics approvals. Aequus will own all clinical results and data generated from trials using the Ehave platform.
Both locations expand access to the state’s widest-ranging inventory of medical cannabis products for Central Florida patients
Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of two brand-new Central Florida dispensaries. The new Clearwater and Tampa locations mark the Company’s 81 st and 82 nd nationwide, respectively, widening patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.
Philip Young, CEO and Director of Lobe, stated, “We are honored to welcome Bart to our Advisory Board. His first-hand experience on and off the field are tremendously valuable as we continue our research involving mild traumatic brain injuries and PTSD. These issues are prevalent in contact sports and we believe that athletes will play a prominent role in the continued acceptance of psychedelic medicines as legitimate treatment. We look forward to working with Bart as we seek to forge long-term strategic relationships.”
HempFusion Wellness Submits Novel Foods Dossier to the United Kingdom’s Regulatory Food Safety Agency
HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that it has submitted its dossier to the United Kingdom’s Regulatory Food Safety Agency (the “FSA”).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210303005322/en/